


Reference Data

(Consolidated Financial Results for Q1 FY2012)



Daiichi-Sankyo

July 31, 2012

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

MEMO

(This page is intentionally left blank)

Contents

1. Consolidated Income Statement	P1
2. Currency Rate	P1
3. Segment Information	P2
4. Sales by Business Units	P3
5. Sales of Global Products	P6
6. Number of Employees	P7
7. Consolidated Balance Sheets	P9
8. Consolidated Statements of Cash Flow	P11
9. Summary of Product Outlines	P12
10. Major R&D Pipeline (Innovative pharmaceuticals)	P13

Supplemental Information

Historical Data

1. Summary of Consolidated Income Statement

Q1				Q2			Q3			Q4			Q1					FY2012			
JPY Bn	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY	to forecast	to sales	Forecast	YoY	YoY
Net sales	100%	242.6	+4.7%										100%	242.6	11.0	+4.7%	25%	100%	980.0	41.3	+4.4%
Cost of sales	27%	66.7	+11.2%										27%	66.7	6.7	+11.2%	22%	30%	297.0	28.4	+10.6%
Gross Profit	73%	176.0	+2.5%										73%	176.0	4.2	+2.5%	26%	70%	683.0	12.9	+1.9%
SG&A expenses	59%	143.4	+11.8%										59%	143.4	15.2	+11.8%	25%	59%	583.0	11.1	+1.9%
R&D expenses	17%	42.0	+2.5%										17%	42.0	1.0	+2.5%	22%	20%	193.0	7.9	+4.3%
A&P expenses	9%	22.7	+9.6%										9%	22.7	2.0	+9.6%			not disclosed		
Personnel expenses	14%	34.7	-0.4%										14%	34.7	-0.1	-0.4%			not disclosed		
Other SG&A expenses	18%	44.0	+39.0%										18%	44.0	12.3	+39.0%			not disclosed		
Operating Income	13%	32.5	-25.2%										13%	32.5	-11.0	-25.2%	33%	10%	100.0	1.8	+1.8%
Non-operating income / expenses		8.3												8.3	6.9				0.0	22.0	
Non-operating income		10.3												10.3	5.8				not disclosed		
Non-operating expenses		2.0												2.0	-1.1				not disclosed		
Ordinary Income	17%	40.8	-9.0%										17%	40.8	-4.0	-9.0%	41%	10%	100.0	23.8	+31.2%
Extraordinary income / losses		0.6												0.6	1.6				-5.0	37.3	
Extraordinary income		2.0												2.0	0.8				not disclosed		
Extraordinary losses		1.5												1.5	-0.8				not disclosed		
Income before income taxes and minority interests	17%	41.4	-5.5%										17%	41.4	-2.4	-5.5%	44%	10%	95.0	61.1	+180.1%
Income taxes / minority interests		21.0												21.0	2.5				45.0	21.5	
Income taxes		16.8												16.8	0.4				not disclosed		
Minority interests		4.2												4.2	2.1				not disclosed		
Net Income	8%	20.4	-19.4%										8%	20.4	-4.9	-19.4%	41%	5%	50.0	39.6	+381.6%
Effective tax rate		41%												41%							
Overseas sales ratio results		54%												54%							

Notes to FY2012 Q1 Results Year-on-Year Comparisons

Net Sales	Ranbaxy +19.4, Mema +2.9, Nexium +1.7, Prasugrel alliance revenue +1.1 Olmesartan -3.3, Plexxikon -2.9, Mevalotin -2.3, Levofloxacin export, royalty, etc -1.9, Luitpold -1.4 (appreciation of JPY to USD and EUR -3.0, appreciation of JPY to INR -9.0)
SG&A expenses	R&D: Forex impact (appreciation of JPY to USD, EUR, and INR) -0.5 Other: Forex impact (appreciation of JPY to USD, EUR, and INR) -6.0, Cost increase from new product launches
Non-operating items	"Forex gains" and "gain on valuation of derivatives" of Ranbaxy

2. Currency Rate

<u>Currency Rate</u>	Q1 Results	Q2 <u>YTD</u> Results	Q3 <u>YTD</u> Results	Q4 <u>YTD</u> Results	Q1 Results	YoY	FY2012 Forecast
USD/JPY (average)	80.21				80.21	-1.54	80.00
EUR/JPY (average)	102.91				102.91	-14.49	100.00
INR/JPY (average)	1.59				1.59	-0.24	-

Appreciation of JPY to USD, EUR, and INR negatively affected the FY2012 Q1 results by 12 bil yen in net sales and 2.5 bil yen in operating income. Annual impact of one yen change is estimated to affect the group's FY2012 performance by; USD: net sales 2 bil yen, operating income minor / EUR: net sales 0.7 bil yen, operating income minor

3. Segment Information

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			Q1			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		183.5	-4.4%											183.5	-8.4	-4.4%
Inter-segment sales		0.3												0.3	0.3	
Net sales	100%	183.8	-4.2%										100%	183.8	-8.1	-4.2%
Cost of sales	26%	47.9	+16.4%										26%	47.9	6.8	+16.4%
Gross Profit	74%	135.9	-9.9%										74%	135.9	-14.9	-9.9%
SG&A expenses	63%	115.9	+4.2%										63%	115.9	4.6	+4.2%
R&D expenses	22%	40.3	+3.1%										22%	40.3	1.2	+3.1%
Other expenses	41%	75.6	+4.8%										41%	75.6	3.4	+4.8%
Operating Income	11%	20.1	-49.3%										11%	20.1	-19.5	-49.3%
Non-operating income		2.1												2.1	-1.7	
Non-operating expenses		1.0												1.0	-0.8	
Ordinary Income	11%	21.1	-49.2%										11%	21.1	-20.5	-49.2%
Extraordinary income		2.0												2.0	0.8	
Extraordinary losses		1.3												1.3	-1.0	
Income before income taxes and minority interests	12%	21.8	-46.2%										12%	21.8	-18.7	-46.2%
Income taxes		8.1												8.1	-9.7	
Minority interests		-0.1												-0.1	0.2	
Net Income	7%	13.7	-40.1%										7%	13.7	-9.2	-40.1%
Ranbaxy Group																
Sales to outside customers		59.1	+48.7%											59.1	19.4	+48.7%
Inter-segment sales		0.7												0.7	0.5	
Net sales	100%	59.8	+49.5%										100%	59.8	19.8	+49.5%
Cost of sales	33%	19.5	+3.7%										33%	19.5	0.7	+3.7%
Gross Profit	67%	40.3	+90.0%										67%	40.3	19.1	+90.0%
SG&A expenses	44%	26.5	+66.2%										44%	26.5	10.6	+66.2%
R&D expenses	3%	2.0	-12.3%										3%	2.0	-0.3	-12.3%
Other expenses	41%	24.5	+79.4%										41%	24.5	10.8	+79.4%
Operating Income	23%	13.8	+161.9%										23%	13.8	8.6	+161.9%
Non-operating income		8.3												8.3	6.5	
Non-operating expenses		0.8												0.8	-0.4	
Ordinary Income	36%	21.2	+269.3%										36%	21.2	15.5	+269.3%
Extraordinary income		0.0												0.0	0.0	
Extraordinary losses		0.1												0.1	0.1	
Income before income taxes and minority interests	35%	21.1	+267.8%										35%	21.1	15.4	+267.8%
Income taxes		6.1												6.1	7.2	
Minority interests		0.0												0.0	-0.0	
Net Income	25%	15.0	+118.9%										25%	15.0	8.2	+118.9%
Inter-segment Transactions																
Net sales		-1.0												-1.0		
Cost of sales		-0.7												-0.7		
Gross Profit		-0.3												-0.3		
SG&A expenses		1.1												1.1		
R&D expenses		-0.3												-0.3		
Other expenses		1.4												1.4		
Operating Income		-1.4												-1.4		
Non-operating income		-0.0												-0.0		
Non-operating expenses		0.1												0.1		
Ordinary Income		-1.5												-1.5		
Extraordinary income		—												—		
Extraordinary losses		0.0												0.0		
Income before income taxes and minority interests		-1.5												-1.5		
Income taxes		2.6												2.6		
Minority interests		4.2												4.2		
Net Income		-8.3												-8.3		

4. Sales by Business Units

	FY2012		Q1			Q2			Q3			Q4			Q1			
	Plan	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
JPY Bn																		
Consolidated Net Sales	980.0	+4.4%	242.6	+4.7%	25%										242.6	11.0	+4.7%	25%
Japan Company (domestic sales)	450.0	+9.8%	98.2	-2.2%	22%										98.2	-2.3	-2.2%	22%
Olmetec	81.0	+0.1%	18.2	-10.8%	23%										18.2	-2.2	-10.8%	23%
Rezaltas	19.0	+41.2%	4.0	+38.6%	21%										4.0	1.1	+38.6%	21%
Calblock	13.0	+5.0%	2.7	-14.0%	21%										2.7	-0.4	-14.0%	21%
Loxonin	62.0	+1.6%	14.1	-2.0%	23%										14.1	-0.3	-2.0%	23%
Cravit	37.0	+1.8%	8.1	-4.2%	22%										8.1	-0.4	-4.2%	22%
Nexium	29.0	+642.5%	1.7	-	6%										1.7	1.7	-	6%
Memary	26.0	+164.3%	5.1	+128.7%	20%										5.1	2.9	+128.7%	20%
Mevalotin	26.0	-21.4%	6.5	-25.7%	25%										6.5	-2.3	-25.7%	25%
Artist	21.0	-14.4%	5.6	-8.9%	27%										5.6	-0.5	-8.9%	27%
Omnipaque	18.0	-23.5%	4.9	-13.2%	27%										4.9	-0.7	-13.2%	27%
Urief	11.0	+0.1%	2.7	+0.5%	24%										2.7	0.0	+0.5%	24%
Inavir	10.0	-6.8%	0.4	+10.3%	4%										0.4	0.0	+10.3%	4%
New Ranmark	5.0	-	0.6	-	12%										0.6	0.6	-	12%
Vaccines	not disclosed	-	5.2	+13.9%	-										5.2	0.6	+13.9%	-
Daiichi Sankyo Espha products	not disclosed	-	2.8	+16.2%	-										2.8	0.4	+16.2%	-
Daiichi Sankyo Healthcare (OTC)	48.0	+4.6%	10.2	+5.0%	21%										10.2	0.5	+5.0%	21%
Daiichi Sankyo, Inc. (US)	115.0	-9.5%	35.9	+3.7%	31%										35.9	1.3	+3.7%	31%
Olmesartan	71.0	-19.2%	23.9	-3.8%	34%										23.9	-1.0	-3.8%	34%
Benicar/Benicar HCT	54.0	-24.2%	18.9	-6.3%	35%										18.9	-1.3	-6.3%	35%
Azor	11.0	-8.6%	3.5	-1.7%	32%										3.5	-0.1	-1.7%	32%
Tribenzor	6.0	+30.0%	1.6	+30.8%	26%										1.6	0.4	+30.8%	26%
Welchol	31.0	+15.4%	8.3	+17.5%	27%										8.3	1.2	+17.5%	27%
Effient (alliance revenue)	not disclosed	-	2.4	+51.8%	-										2.4	0.8	+51.8%	-
Luitpold Pharmaceuticals, Inc. (US)	44.0	-1.7%	11.3	-10.9%	26%										11.3	-1.4	-10.9%	26%
Venofer	23.0	-7.4%	6.8	-7.4%	30%										6.8	-0.5	-7.4%	30%
Daiichi Sankyo Europe GmbH	65.0	-7.4%	13.9	-17.6%	21%										13.9	-3.0	-17.6%	21%
Olmesartan	48.0	-5.9%	9.9	-16.6%	21%										9.9	-2.0	-16.6%	21%
Olmetec/Olmetec Plus	34.0	-7.2%	6.4	-26.5%	19%										6.4	-2.3	-26.5%	19%
Sevikar	10.0	-8.9%	2.5	+4.5%	25%										2.5	0.1	+4.5%	25%
Sevikar HCT	4.0	+18.3%	1.0	+31.6%	24%										1.0	0.2	+31.6%	24%
Efient (alliance revenue)	not disclosed	-	0.9	+54.7%	-										0.9	-	+54.7%	-

	FY2012		Q1			Q2			Q3			Q4			Q1			
	Plan	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
Asia, South and Central America (ASCA) *1	38.0	+27.8%	7.1	+9.8%	19%										7.1	0.6	+9.8%	19%
Daiichi Sankyo China *2	not disclosed	-	2.7	+0.9%	-										2.7	0.9	+0.9%	-
Daiichi Sankyo Taiwan	not disclosed	-	0.8	-5.9%	-										0.8	0.0	-5.9%	-
Daiichi Sankyo Korea	not disclosed	-	1.2	+2.1%	-										1.2	0.0	+2.1%	-
Daiichi Sankyo (Thailand)	not disclosed	-	0.3	+3.7%	-										0.3	0.0	+3.7%	-
Daiichi Sankyo Brasil Farmacêutica	not disclosed	-	1.2	+14.2%	-										1.2	0.2	+14.2%	-
Daiichi Sankyo Venezuela	not disclosed	-	0.8	+87.0%	-										0.8	0.4	+87.0%	-
Daiichi Sankyo Mexico S.A. de C.V	not disclosed	-	0.1	-	-										0.1	0.1	-	-
Ranbaxy Laboratories Limited	179.0	+2.0%	59.1	+48.7%	33%										59.1	19.4	+48.7%	33%
Others	41.0	+14.7%	6.8	-38.0%	17%										6.8	-4.2	-38.0%	17%
Levofloxacin export, royalty, etc	3.0	-63.2%	1.2	-60.1%	41%										1.2	-1.9	-60.1%	41%
Plexxikon	not disclosed	-	0.1	-96.1%	-										0.1	-2.9	-96.1%	-

Currency rates for overseas subsidiaries

	Plan	Q1 Results	Q2 YTD Results	Q3 YTD Results	Q4 YTD Results	Q1 Results
USD/JPY (average)	80.00	80.21				80.21
EUR/JPY (average)	100.00	102.91				102.91
INR/JPY (average)	-	1.59				1.59

New Product Launches

Apr 2012: Ranmark (anti-RANKL antibody for the treatment of bone complications stemming from multiple myeloma and bone metastases from solid tumors) launched in Japan.

Notes

*1 Since companies in China, Brazil, Venezuela and Mexico will change their fiscal year-ends from December to March, their FY2012 financial results will be for 15 months.

*2 Daiichi Sankyo Pharmaceutical (Beijing) and Daiichi Sankyo Pharmaceutical (Shanghai) are consolidated as Daiichi Sankyo China.

[Reference] Sales in Local Currency

		FY2012		Q1			Q2			Q3			Q4			Q1			
		Plan	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
USD Mn																			
Daiichi Sankyo, Inc. (US)		1,438	-10.6%	448	+5.7%	31%										448	24	+5.7%	31%
Olmesartan		888	-20.2%	298	-2.0%	34%										298	-6	-2.0%	34%
Benicar/Benicar HCT		675	-25.1%	235	-4.5%	35%										235	-11	-4.5%	35%
Azor		138	-9.6%	44	+0.2%	32%										44	0	+0.2%	32%
Tribenzor		75	+28.5%	19	+33.3%	26%										19	5	+33.3%	26%
Welchol		388	+14.1%	103	+19.7%	27%										103	17	+19.7%	27%
Effient (alliance revenue)		not disclosed	-	30	+54.7%	-										30	11	+54.7%	-
USD Mn																			
Luitpold Pharmaceuticals, Inc. (US)		550	-2.8%	141	-9.2%	26%										141	-14	-9.2%	26%
Venofer		288	-8.5%	85	-5.6%	30%										85	-5	-5.6%	30%
EUR Mn																			
Daiichi Sankyo Europe GmbH		650	+0.9%	135	-6.0%	21%										135	-9	-6.0%	21%
Olmesartan		480	+2.5%	96	-4.8%	20%										96	-5	-4.8%	20%
Olmetec/Olmetec Plus		340	+1.1%	62	-16.2%	18%										62	-12	-16.2%	18%
Sevikar		100	-0.7%	24	+19.3%	25%										24	4	+19.3%	25%
Sevikar HCT		40	+28.9%	9	+50.1%	24%										9	3	+50.1%	24%
Efient (alliance revenue)		not disclosed	-	9	+76.5%	-										9	4	+76.5%	-
INR Bn																			
Ranbaxy Laboratories Limited		105	+3.8%	37	+71.1%	35%										37	15	+71.1%	35%

5. Sales of Global Products

	FY2012		Q1			Q2			Q3			Q4			Q1			
	Plan	YoY	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	YoY	to plan
JPY Bn																		
Olmesartan	237.0	-5.1%	60.0	-5.3%	25%										60.0	-3.3	-5.3%	25%
Olmetec (JPN)	81.0	+0.1%	18.2	-10.8%	23%										18.2	-2.2	-10.8%	23%
Rezaltas (JPN)	19.0	+41.2%	4.0	+38.6%	21%										4.0	1.1	+38.6%	21%
Benicar/Benicar HCT (US)	54.0	-24.2%	18.9	-6.3%	35%										18.9	-1.3	-6.3%	35%
Azor (US)	11.0	-8.6%	3.5	-1.7%	32%										3.5	-0.1	-1.7%	32%
Tribenzor (US)	6.0	+30.0%	1.6	+30.8%	26%										1.6	0.4	+30.8%	26%
Olmetec/Olmetec Plus (EU)	34.0	-7.2%	6.4	-26.5%	19%										6.4	-2.3	-26.5%	19%
Sevikar (EU)	10.0	-8.9%	2.5	+4.5%	25%										2.5	0.1	+4.5%	25%
Sevikar HCT (EU)	4.0	+18.3%	1.0	+31.6%	24%										1.0	0.2	+31.6%	24%
Other subsidiaries, export, etc	18.0	+9.2%	4.0	+20.5%	22%										4.0	0.7	+20.5%	22%
Prasugrel	not disclosed	-	3.3	+52.6%	-										3.3	1.1	+52.6%	-
Effient alliance revenue (US)	not disclosed	-	2.4	+51.8%	-										2.4	0.8	+51.8%	-
Efient alliance revenue (EU)	not disclosed	-	0.9	+54.7%	-										0.9	0.3	+54.7%	-

6. Number of Employees

	Mar 2012 Results	Jun 2012 Results	Sep 2012 Results	Dec 2012 Results	Mar 2013 Results
Total Number of Employees	31,929	32,522			
Japan	9,308	9,435			
* Overseas	22,621	23,087			
Daiichi Sankyo Group	17,877	18,043			
* Ranbaxy Group	14,052	14,479			

* For overseas subsidiaries with different fiscal year-ends, numbers as of Mar-end are shown in the Junr-end columns

MEMO

(This page is intentionally left blank)

7. Consolidated Balance Sheets

(Billions of yen)

	Mar 2012	Jun 2012	YoY	Notes
ASSETS				
Current assets				
Cash and time deposits	128.9	146.7	17.8	<div> <div></div> <div>PBT +41.4 Bn, Acquisitions of proceeds from sales of non-current assets -17.5 Bn Dividend paid -21.1 Bn, Income taxes paid -9.7 Bn</div> </div>
Trade notes and accounts receivable	228.5	218.2	-10.3	
Marketable securities	191.3	174.8	-16.5	
Inventories	169.7	173.7	4.0	
Deferred tax assets	94.0	94.8	0.8	
Other current assets	51.3	46.3	-5.0	
Allowance for doubtful accounts	-2.2	-2.4	-0.2	
Total current assets	861.5	852.0	-9.5	
Non-current assets				
Property, plant and equipment				
Buildings and structures, net	129.3	132.5	3.2	
Machinery, equipment and vehicles, net	48.1	49.5	1.4	
Land	35.7	36.2	0.5	
Construction in progress	33.7	38.6	4.9	
Other, net	14.5	15.0	0.5	
Total property, plant and equipment	261.2	271.8	10.5	Newly added: Daiichi Sankyo +5.0 Bn, Kitasato Daiichi Sankyo Vaccine (KDSV) +4.0 Bn
Intangible assets				
Goodwill, net	82.7	79.0	-3.8	
Other intangible assets, net	150.5	146.5	-4.1	
Total intangible assets	233.3	225.4	-7.9	
Investments and other assets				
Investment securities	104.6	102.7	-1.8	
Deferred tax assets	43.2	42.4	-0.8	
Other	15.0	15.0	0.1	
Allowance for doubtful accounts	-0.3	-0.3	0.0	
Total investments and other assets	162.4	159.9	-2.5	
Total non-current assets	656.9	657.1	0.2	
Total assets	1,518.5	1,509.1	-9.3	

(Billions of yen)

	Mar 2012	Jun 2012	YoY	Notes
LIABILITIES				
Current liabilities				
Trade notes and accounts payable	61.8	56.4	-5.4	
Short-term bank loans	71.1	71.7	0.6	
Income taxes payable	5.3	5.0	-0.3	
Allowance for sales returns	0.6	0.6	0.0	
Allowance for sales rebates	2.9	2.4	-0.5	
Provision for loss on disaster	0.8	0.5	-0.3	
Provision for settlement expenses	39.1	41.2	2.1	
Other current liabilities	213.3	210.9	-2.4	
Total current liabilities	395.0	388.7	-6.3	
Long-term liabilities				
Bonds payable	100.0	100.0	0.0	
Long-term debt	104.0	104.7	0.7	
Deferred tax liabilities	52.1	52.1	0.0	
Accrued employees' severance and retirement benefits	10.1	11.3	1.2	
Accrued directors' severance and retirement benefits	0.2	0.2	0.0	
Provision for environment measures	1.2	0.9	-0.3	
Other long-term liabilities	23.2	22.7	-0.4	
Total long-term liabilities	290.8	292.0	1.2	
Total liabilities	685.7	680.7	-5.0	
NET ASSETS				
Shareholders' equity				
Common stock	50.0	50.0	0.0	
Capital surplus	105.2	105.2	0.0	
Retained earnings	742.4	741.7	-0.7	Net income +20.4 Bn, Dividend paid -21.1 Bn
Treasury stock, at cost	-14.6	-14.6	0.0	
Total shareholders' equity	883.0	882.3	-0.7	
Accumulated other comprehensive income				
Net unrealized gain on investment securities	22.3	21.5	-0.8	
Deferred gains or losses on hedges	0.2	0.6	0.4	
Foreign currency translation adjustments	-100.6	-110.1	-9.5	Decrease in net assets of overseas subsidiaries in JPY basis -9.5 Bn
Total accumulated other comprehensive income	-78.1	-88.1	-10.0	
Subscription rights to shares	3.5	3.8	0.3	
Minority interests	24.3	30.3	6.0	Ranbaxy +6.1 Bn
Total net assets	832.7	828.4	-4.3	
Total liabilities and net assets	1,518.5	1,509.1	-9.3	

8. Consolidated Statements of Cash Flows

(Billions of yen)

	FY2011 Q1 Results	FY2012 Q1 Results	YoY	Notes
Cash flows from operating activities				
Income before income taxes and minority interests	43.8	41.4	-2.4	
Depreciation and amortization of goodwill	13.5	12.9	-0.6	
Increase/decrease in trade receivable and payable	-4.1	-1.2	2.9	
Other, net	-9.9	-5.2	4.7	
Income taxes paid	-8.7	-9.7	-1.0	
Net cash provided by operating activities	34.4	38.2	3.8	
Cash flows from investing activities				
Net increase (decrease) in short-term investments	49.3	-75.3	-124.6	
(Acquisition of) proceeds from sales of non-current assets	-7.6	-17.5	-9.9	
Acquisition of investments in subsidiaries	-65.6	0.0	65.6	FY2011: Plexxikon (-65.6 Bn)
Other, net	-18.7	4.5	23.2	FY2011: Kitasato Daiichi Sankyo Vaccine (KDSV) - Payment for transfer of business (-16.1 Bn)
Net cash used in investing activities	-42.6	-88.3	-45.7	
Cash flows from financing activities				
Net increase (decrease) in loans payable	2.3	-2.5	-4.8	
Redemption of bonds	-47.6	—	47.6	FY2011: Redemption of Ranbaxy's Foreign Currency Convertible Bond
Dividends paid	-21.1	-21.1	0.0	
Other, net	11.3	0.1	-11.2	FY2011: Investment in KDSV from The Kitasato Institute
Net cash used in financing activities	-55.1	-23.6	31.5	
Effect of exchange rate changes on cash and cash equivalents	-1.0	-0.6	0.4	
Net increase (decrease) in cash and cash equivalents	-64.3	-74.3	-10.0	
Cash and cash equivalents, beginning of period	302.4	212.7	-89.7	
Cash and cash equivalents, at end of period	238.1	138.4	-99.7	

9. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance
Japan Company (domestic sales)					
Olmetec	olmesartan	antihypertensive	2004	Daiichi Sankyo	Kowa
Rezaltas	olmesartan / azelnidipine	antihypertensive	2010	Daiichi Sankyo	
Calblock	azelnidipine	antihypertensive	2003	Ube Industries	
Loxonin			1986	Daiichi Sankyo	
Loxonin Poultice			2006	Lead Chemical	
Loxonin Tape	loxoprofen	analgesic and anti-inflammatory	2008	Lead Chemical	
Loxonin Gel			2010	Daiichi Sankyo	
Cravit	levofloxacin	antibacterial	1993	Daiichi Sankyo	
Nexium	esomeprazole	proton pump inhibitor	2011	AstraZeneca	AstraZeneca
Memary	memantine	treatment for Alzheimer's Disease	2011	Merz	
Mevalotin	pravastatin	antihyperlipidemic	1989	Daiichi Sankyo	
Artist	carvedilol	antihypertensive	1993	Roche	
Omnipaque	iohexol	contrast medium	1987	GE Healthcare	
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei
Inavir	laninamivir	anti-influenza	2010	Daiichi Sankyo	
Ranmark	denosumab	anti-RANKL antibody	2011	Amgen	AstraZeneca
Daiichi Sankyo, Inc. (US)					
Olmesartan					
Benicar	olmesartan		2002		
Benicar HCT	olmesartan / hydrochlorothiazide	antihypertensive	2003	Daiichi Sankyo	
Azor	olmesartan / amlodipine		2007		
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010		
Welchol	colesevelam	antihyperlipidemic / type 2 diabetes	2000	Genzyme	
Effient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly
Luitpold Pharmaceuticals, Inc. (US)					
Venofer	iron sucrose injection	iron deficiency anemia	2000	Vifor Pharma	Fresenius
Daiichi Sankyo Europe GmbH					
Olmesartan					
Olmetec	olmesartan		2002		
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive	2005	Daiichi Sankyo	Menarini Pfizer Nycomed
Sevikar	olmesartan / amlodipine		2009		
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010		
Efient	prasugrel	antiplatelet	2009	Daiichi Sankyo Ube Industries	Lilly

10. Major R&D Pipeline (Innovative pharmaceuticals)

Therapeutic Area	Development code Number	Generic Name	Class	Target indication	Stage		Remarks
Cardiovascular - Metabolics	DU-176b	edoxaban	Factor Xa inhibitor	Atrial Fibrillation (AF) Venous thromboembolism (VTE)	Global Global	P3 P3	Study to be completed in FY2012 Enrollment to be completed in FY2012
	CS-747	prasugrel	Anti-platelet agent	Acute coronary syndrome(ACS-MM) Acute coronary syndrome(ACS-PCI) Elective PCI Ischemic Stroke Sickle cell disease	Global JP JP JP US	P3 P3 P3 P3 P2	Study results to be presented on 26 Aug at ESC Application to be expected in FY2013 Applicaition to be expected in FY2013 Study to be completed in FY2014
	CS-3150	-	-	Hypertension	-	P1	
	DS-7309	-	-	Diabetes	-	P1	
	DS-7250	-	-	Diabetes	-	P1	
	DS-6930	-	-	Diabetes	-	P1	
	AMG 162	denosumab	Anti-RANKL antibody	Breast cancer adjuvant Giant cell tumor	JP JP	P3 P2	
	ARQ 197	tivantinib	Met inhibitor	Non small cell lung cancer Hepatocellular cancer Colorectal cancer	Global US/EU US/EU	P3 P2 P2	(Study ongoing outside Japan)
Oncology	CS-1008	tigatuzumab	Anti-DR5 antibody	Hepatocellular cancer	Global	P2	
	DE-766	nimotuzumab	Anti-EGFR antibody	Gastric cancer Non small cell lung cancer Esophageal cancer	JP JP JP	P2 P2 P1	
	CS-7017	efatutazone	PPAR-gamma agonist	Non small cell lung cancer Colorectal cancer Non small cell lung cancer Colorectal cancer	US/EU US/EU Asia JP	P2 P2 P1 P1	
	U3-1287	-	Anti-HER3 antibody	Non small cell lung cancer Non small cell lung cancer Breast cancer Breast cancer	US/EU JP US JP	P2 P1 P2 P1	
	PLX4032	vemurafenib	BRAF inhibitor	Thyroid cancer	US/EU	P2	
	PLX3397	-	Fms/Kit/Flt3-ITD inhibitor	Hodgkin lymphoma Acute myeloid leukemia Glioblastoma Prostate Caner	US US US US	P2 P2 P2 P2	
	U3-1565	-	Anti-HB-EGF antibody	Solid cancer	US/JP	P1	
	DS-2248	-	HSP90 inhibitor	Solid cancer	US	P1	
	DS-7423	-	PI3K/mTOR inhibitor	Solid cancer	US JP	P1 P1	
	ARQ 092	-	AKT inhibitor	Solid cancer	US	P1	
	DS-3078	-	mTOR inhibitor	Solid cancer, lymphoma	US/EU	P1	
	AMG162	denosumab	Anti-RANKL antibody	Osteoporosis Rheumatoid arthritis	JP JP	Application P2	Application in Mar 2012
	CS-8958	laninamivir	Neuraminidase inhibitor	Anti-influenza, prophylactic Anti-influenza	JP US/EU	P3 P1	
	DR-3355	levofloxacin	New quinolone	Anti-infection	JP	P3	
Others	DD-723-B	perflubutane	Ultrasound contrast agent	Contrast enhanced ultrasonography for breast tumor Contrast enhanced ultrasonography for prostate tumor	JP JP	Application P3	Application in Dec 2011
	DS-5565	-	$\alpha 2\delta$ ligand	Chronic pain	Global	P2	
	SUN13837	-	Modulator of bFGF signaling system	Spinal cord injury	US	P2	
	DS-8587	-	-	Antibacterial	-	P1	
	CS-4771	-	-	Anti-sepsis	-	P1	
	PLX5622	-	-	Rheumatoid arthritis	-	P1	
	CS-0777	-	-	Immunomodulator	-	P1	
	ASB17061	-	-	Atopic Dermatitis	-	P1	
	DS-7113	hydromorphone	opioid mu-receptor regulator	Narcotic analgesic	-	P1	

Change from announcement in May 2012

■ Change of stage

Therapeutic Area	Development code Number	Generic Name	Class	Target indication	Stage	
Others	DR-3355	levofloxacin	New quinolone	Anti-infection	JP	P3
Oncology	PLX3397	-	Fms/Kit/Flt3-ITD inhibitor	Prostate Caner	US	P2
Others	SUN13837	-	Modulator of bFGF signaling system	Spinal cord injury	US	P2
Cardiovascular - Metabolics	DS-6930	-	-	Diabetes	-	P1
Oncology	U3-1287	-	Anti-HER3 antibody	Breast cancer	JP	P1
Oncology	DS-7423	-	PI3K/mTOR inhibitor	Solid cancer	JP	P1
Others	ASB17061	-	-	Atopic Dermatitis	-	P1
Others	DS-7113	hydromorphone	opioid mu-receptor regulator	Narcotic analgesic	-	P1

■ Discontinue

Therapeutic Area	Development code Number	Generic Name	Class	Target indication	Stage	
Others	SUN13834	-	Chymase inhibitor	Atopic Dermatitis	US	P2
	< Reason for discontinue > Expected goal was not achieved.					

1. Summary of Consolidated Income Statement (FY2011)

JPY Bn	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	231.7	-9.7%	100%	224.4	-7.5%	100%	240.4	-3.5%	100%	242.3	+10.5%	100%	938.7	-28.7	-3.0%
Cost of sales	26%	59.9	-6.5%	31%	69.0	-7.4%	30%	71.7	-3.9%	28%	68.1	-0.8%	29%	268.6	-13.1	-4.6%
Gross Profit	74%	171.8	-10.7%	69%	155.4	-7.5%	70%	168.7	-3.4%	72%	174.2	+15.6%	71%	670.1	-15.6	-2.3%
SG&A expenses	55%	128.3	-2.3%	61%	136.7	-1.6%	58%	139.0	-3.5%	69%	167.9	+12.5%	61%	571.9	8.3	+1.5%
R&D expenses	18%	41.0	-5.9%	19%	43.0	-5.8%	19%	44.7	-15.6%	23%	56.3	+8.2%	20%	185.1	-9.3	-4.8%
A&P expenses	9%	20.7	-9.4%	11%	23.7	-4.6%	10%	24.8	-4.1%	11%	26.5	+1.4%	10%	95.7	-4.0	-4.0%
Personnel expenses	15%	34.9	+0.8%	16%	35.6	+0.5%	14%	33.7	+1.9%	14%	34.8	+0.0%	15%	139.0	1.1	+0.8%
Other SG&A expenses	14%	31.6	+4.6%	15%	34.4	+4.1%	15%	35.7	+11.3%	21%	50.4	+38.7%	16%	152.1	20.4	+15.5%
Operating Income	19%	43.5	-28.8%	8%	18.7	-35.6%	12%	29.7	-2.8%	3%	6.3	+318.5%	10%	98.2	-23.9	-19.6%
Non-operating income / expenses		1.4			2.8			-9.6			-16.5			-22.0	-31.6	
Non-operating income		4.5			4.8			-1.0			1.7			10.0	-13.2	
Non-operating expenses		3.1			2.0			8.6			18.3			32.0	18.4	
Ordinary Income	19%	44.8	-36.0%	10%	21.5	-4.6%	8%	20.1	-47.1%	-4%	-10.2	-	8%	76.2	-55.5	-42.2%
Extraordinary income / losses		-1.1			-3.2			-41.7			3.7			-42.3	-31.0	
Extraordinary income		1.2			0.7			0.2			12.7			14.8	2.0	
Extraordinary losses		2.3			4.0			41.9			9.0			57.1	32.9	
Income before income taxes and minority interests	19%	43.8	-33.8%	8%	18.3	-34.8%	-9%	-21.6	-	-3%	-6.5	-	4%	33.9	-86.5	-71.8%
Income taxes / minority interests		18.5			6.5			-2.1			0.7			23.5	-26.8	
Income taxes		16.4			6.3			15.2			1.8			39.8	-2.0	
Minority interests		2.1			0.2			-17.4			-1.2			-16.2	-24.7	
Net Income	11%	25.3	-23.5%	5%	11.7	-38.5%	-8%	-19.5	-	-3%	-7.2	-	1%	10.4	-59.7	-85.2%
Effective tax rate		37%			34%			-			-			117%		
Overseas sales ratio results		51%			48%			45%			56%			50%		

2. Currency Rate (FY2011)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2011
	Results	Results	Results	Results	Results YoY
USD/JPY (average)	81.75	79.81	79.00	79.07	79.07 -6.65
EUR/JPY (average)	117.40	113.78	110.62	108.96	108.96 -4.17
INR/JPY (average)	1.83	1.83	1.79	1.73	1.73 -0.20

3. Segment Information (FY2011)

Daiichi Sankyo Group	Q1			Q2			Q3			Q4			FY2011			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Sales to outside customers		191.9	-4.8%		185.9	-6.5%		204.7	-4.2%		180.6	-0.4%		763.2	-32.2	-4.2%
Inter-segment sales		0.1			0.1			0.3			-0.0			0.5	0.4	
Net sales	100%	192.0	-4.8%	100%	186.0	-6.4%	100%	205.0	-4.1%	100%	180.6	-0.4%	100%	763.6	-31.8	-4.0%
Cost of sales	21%	41.1	-8.4%	26%	48.3	-11.2%	26%	52.5	-4.4%	25%	45.2	-5.0%	25%	187.1	-14.7	-7.3%
Gross Profit	79%	150.8	-3.8%	74%	137.7	-4.6%	74%	152.5	-3.9%	75%	135.4	+1.2%	76%	576.5	-17.2	-2.9%
SG&A expenses	58%	111.2	-2.0%	64%	119.1	-1.8%	60%	122.3	-4.2%	78%	140.2	+6.6%	65%	492.8	-1.0	-0.2%
R&D expenses	20%	39.1	-3.1%	22%	40.9	-5.9%	21%	42.7	-15.6%	30%	54.2	+9.4%	23%	177.0	-7.0	-3.8%
Other expenses	38%	72.1	-1.4%	42%	78.1	+0.5%	39%	79.6	+3.3%	48%	86.0	+5.0%	41%	315.9	6.0	+1.9%
Operating Income	21%	39.6	-8.5%	10%	18.7	-19.4%	15%	30.2	-2.9%	-3%	-4.8	-	11%	83.7	-16.1	-16.2%
Non-operating income		3.8			1.7			1.6			1.0			8.1	0.9	
Non-operating expenses		1.8			1.4			0.7			0.9			4.8	-2.3	
Ordinary Income	22%	41.6	-4.2%	10%	19.0	-17.8%	15%	31.1	-7.9%	-3%	-4.6	-	11%	87.0	-13.0	-13.0%
Extraordinary income		1.2			0.7			-0.0			12.5			14.3	4.1	
Extraordinary losses		2.3			3.8			1.5			8.1			15.7	-5.2	
Income before income taxes and minority interests	21%	40.4	+1.2%	9%	15.8	-38.9%	14%	29.5	-14.2%	0%	-0.2	-	11%	85.6	-3.7	-4.2%
Income taxes		17.8			5.9			18.9			8.6			51.2	20.7	
Minority interests		-0.2			-0.8			-0.4			-1.6					
Net Income	12%	22.9	+2.5%	6%	10.7	-41.9%	5%	11.0	-57.5%	-4%	-7.2	-	5%	37.4	-21.4	-36.4%
Ranbaxy Group																
Sales to outside customers		39.8	-27.5%		38.4	-12.0%		35.7	+0.6%		61.6	+62.3%		175.5	3.6	+2.0%
Inter-segment sales		0.2			0.2			0.2			0.4			1.1	-0.0	
Net sales	100%	40.0	-27.1%	100%	38.6	-11.7%	100%	35.9	+1.1%	100%	62.0	+59.5%	100%	176.6	3.5	+2.0%
Cost of sales	47%	18.8	-2.2%	54%	20.7	+3.3%	54%	19.5	-0.1%	37%	22.8	+8.2%	46%	81.7	2.0	+2.5%
Gross Profit	53%	21.2	-40.6%	46%	17.9	-24.5%	46%	16.4	+2.5%	63%	39.3	+120.0%	54%	94.8	1.5	+1.7%
SG&A expenses	40%	15.9	-2.6%	42%	16.3	-5.0%	43%	15.6	+1.2%	43%	26.7	+59.6%	42%	74.4	8.9	+13.5%
R&D expenses	6%	2.3	-30.8%	6%	2.4	-21.3%	6%	2.3	-19.1%	4%	2.3	-17.9%	5%	9.3	-2.7	-22.6%
Other expenses	34%	13.7	+4.5%	36%	13.9	-1.4%	37%	13.3	+5.8%	39%	24.3	+75.4%	37%	65.1	11.6	+21.6%
Operating Income	13%	5.3	-72.7%	4%	1.7	-74.9%	2%	0.9	+34.5%	20%	12.6	+998.6%	12%	20.4	-7.3	-26.4%
Non-operating income		1.7			3.1			-2.5			0.8			3.2	-13.0	
Non-operating expenses		1.3			0.5			7.9			17.4			27.0	23.1	
Ordinary Income	14%	5.8	-79.6%	11%	4.2	+353.5%	-26%	-9.5	-	-6%	-3.9	-	-2%	-3.4	-43.4	-
Extraordinary income		0.0			0.0			0.8			0.2			1.1	-4.1	
Extraordinary losses		0.0			0.1			0.0			41.2			41.4	33.1	
Income before income taxes and minority interests	14%	5.7	-79.2%	11%	4.2	-31.2%	-24%	-8.7	-	-72%	-45.0	-	-25%	-43.8	-80.6	-
Income taxes		-1.1			0.6			-3.2			-6.5			-10.2	-23.4	
Minority interests		0.0			0.0			0.0			0.0			0.2	-0.1	
Net Income	17%	6.9	-62.7%	9%	3.5	-22.7%	-16%	-5.6	-	-62%	-38.5	-	-19%	-33.7	-57.1	-
Inter-segment Transactions																
Net sales		-0.3			-0.3			-0.6			-0.4			-1.5		
Cost of sales		0.0			-0.1			-0.3			0.1			-0.3		
Gross Profit		-0.3			-0.2			-0.2			-0.5			-1.3		
SG&A expenses		1.1			1.4			1.1			1.0			4.6		
R&D expenses		-0.4			-0.3			-0.3			-0.3			-1.2		
Other expenses		1.4			1.7			1.4			1.3			5.8		
Operating Income		-1.4			-1.6			-1.3			-1.5			-5.9		
Non-operating income		-1.1			-0.1			-0.1			-0.1			-1.3		
Non-operating expenses		0.0			0.0			0.1			0.0			0.1		
Ordinary Income		-2.5			-1.7			-1.5			-1.7			-7.3		
Extraordinary income		0.1			0.0			-0.7			0.0			-0.6		
Extraordinary losses								40.3			-40.3			0.0		
Income before income taxes and minority interests		-2.4			-1.7			-42.5			38.7			-7.9		
Income taxes		-0.3			-0.2			-0.5			-0.2			-1.3		
Minority interests		2.3			1.0			-17.0			0.4			-13.4		
Net Income		-4.4			-2.4			-24.9			38.5			6.7		

4. Sales by Business Units (FY2011)

JPY Bn	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
Consolidated Net Sales	231.7	-9.7%	24%	224.4	-7.5%	23%	240.4	-3.5%	25%	242.3	+10.5%	25%	938.7	-3.0%	97%
Japan Company (domestic sales)	100.4	-4.6%	23%	100.5	-2.4%	23%	113.9	-2.4%	26%	94.9	+4.3%	22%	409.8	-1.5%	94%
Olmetec	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Calblock	3.2	-13.4%	21%	3.2	-9.4%	21%	3.3	-13.8%	22%	2.7	-7.5%	18%	12.4	-11.3%	83%
Loxonin	14.4	+10.7%	25%	15.7	+13.3%	27%	17.2	+17.6%	30%	13.7	+8.3%	24%	61.0	+12.7%	105%
Cravit	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Nexium	-	-	-	2.6	-	-	0.6	-	-	0.7	-	-	3.9	-	-
Memary	2.2	-	-	1.6	-	-	2.8	-	-	3.2	-	-	9.8	-	-
Mevalotin	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Artist	6.1	+0.0%	27%	6.2	+6.8%	27%	6.5	+3.6%	29%	5.6	+3.7%	25%	24.5	+3.5%	107%
Omnipaque	5.7	-11.6%	25%	6.3	-5.1%	27%	6.4	-2.0%	28%	5.2	-4.5%	23%	23.5	-5.8%	102%
Urief	2.6	+6.8%	24%	2.8	+13.6%	25%	3.0	+7.6%	27%	2.6	+9.2%	23%	11.0	+9.3%	100%
Inavir	0.4	-	4%	-0.1	-	-	1.7	-38.5%	19%	8.7	+125.1%	97%	10.7	+61.7%	119%
Vaccines	4.6	+166.4%	-	5.3	+14.8%	-	6.9	-19.7%	-	4.5	+56.5%	-	21.2	+19.6%	-
Daiichi Sankyo Espha products	2.4	-	-	2.4	-	-	2.9	-	-	2.1	-	-	9.9	-	-
Daiichi Sankyo Healthcare (OTC)	9.7	+4.9%	20%	12.7	+8.2%	26%	13.7	+4.1%	28%	9.7	-8.5%	20%	45.9	+2.3%	94%
Daiichi Sankyo, Inc. (US)	34.6	+3.2%	27%	29.7	-12.4%	23%	30.1	-13.0%	23%	32.6	+15.0%	25%	127.1	-2.6%	98%
Olmesartan	24.9	-1.5%	28%	20.4	-17.4%	23%	20.6	-16.3%	23%	22.1	+10.7%	25%	87.9	-6.9%	100%
Benicar/Benicar HCT	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Welchol	7.0	+0.5%	22%	6.5	-11.5%	20%	6.6	-16.0%	21%	6.7	+6.7%	21%	26.9	-5.8%	84%
Effient (alliance revenue)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Luitpold Pharmaceuticals, Inc. (US)	12.7	-13.6%	26%	9.3	-31.7%	19%	15.0	+31.0%	31%	7.6	-45.6%	16%	44.7	-17.0%	91%
Venofer	7.4	-12.5%	30%	5.5	-28.5%	22%	9.1	+55.6%	36%	2.9	-66.8%	12%	24.8	-19.0%	99%
Daiichi Sankyo Europe GmbH	16.9	+14.0%	22%	16.9	+2.0%	22%	17.4	-4.3%	23%	19.1	+13.0%	25%	70.2	+5.7%	91%
Olmesartan	11.9	+23.5%	22%	12.2	+4.2%	22%	12.7	-5.4%	23%	14.3	+24.4%	26%	51.0	+10.5%	93%
Olmetec/Olmetec Plus	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Efient (alliance revenue)	0.6	-	-	0.6	-	-	0.7	-	-	1.0	-	-	2.9	-	-
Asia, South and Central America (ASCA)	6.5	+8.7%	22%	7.3	+3.8%	24%	6.9	+2.0%	23%	7.8	+2.8%	26%	28.6	+4.1%	95%
Daiichi Sankyo Pharmaceutical (Beijing)	0.9	-19.9%	-	0.9	-15.0%	-	0.8	-28.4%	-	0.8	-11.1%	-	3.4	-18.9%	-
Daiichi Sankyo Pharmaceutical (Shanghai)	1.7	+21.9%	-	1.7	-3.8%	-	1.3	-18.7%	-	1.6	-11.3%	-	6.3	-3.9%	-
Daiichi Sankyo Taiwan	0.8	+4.6%	-	0.8	-2.8%	-	0.8	-2.7%	-	0.8	-21.0%	-	3.1	-6.3%	-
Daiichi Sankyo Korea	1.2	+23.0%	-	1.1	+27.0%	-	1.1	+14.6%	-	1.1	-0.7%	-	4.6	+15.2%	-
Daiichi Sankyo (Thailand)	0.3	+10.1%	-	0.3	+2.3%	-	0.3	-1.6%	-	0.3	-7.5%	-	1.2	-0.1%	-
Daiichi Sankyo Brasil Farmacêutica	1.1	+2.6%	-	1.5	+4.4%	-	1.5	+6.7%	-	1.5	+13.1%	-	5.5	+6.9%	-
Daiichi Sankyo Venezuela	0.5	+22.5%	-	1.0	+33.2%	-	1.1	+74.6%	-	1.6	+43.6%	-	4.2	+45.1%	-
Daiichi Sankyo Mexico S.A. de C.V	-	-	-	-	-	-	0.1	-	-	0.1	-	-	0.2	-	-
Ranbaxy Laboratories Limited	39.8	-27.5%	25%	38.4	-12.0%	24%	35.7	+0.6%	22%	61.6	+62.3%	38%	175.5	+2.1%	108%
Others	11.1	-38.7%	29%	9.5	-25.9%	25%	7.5	-40.5%	20%	8.8	-31.2%	23%	36.9	-34.5%	97%
Levofloxacin export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Plexxikon	3.0	-	-	1.9	-	-	0.3	-	-	0.8	-	-	5.9	-	-

[Reference] Sales in Local Currency

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
USD Mn															
Daiichi Sankyo, Inc. (US)	424	+16.1%	27%	382	-2.9%	24%	390	-7.5%	25%	412.0	+20.3%	26%	1,608	+5.6%	103%
Olmesartan	304	+10.9%	29%	263	-8.4%	25%	266	-11.2%	25%	278	+15.7%	26%	1,112	+0.9%	105%
Benicar/Benicar HCT	246	+5.7%	31%	217	-10.0%	27%	210	-16.5%	26%	228	+11.5%	28%	901	-3.1%	112%
Azor	43	+4.7%	27%	32	-18.4%	20%	41	-3.5%	25%	36	+11.9%	22%	152	-1.9%	94%
Tribenzor	14	-	16%	14	+96.0%	16%	15	+158.0%	17%	14	+287.9%	16%	58	+244.1%	65%
Welchol	86	+13.2%	22%	84	-1.9%	22%	85	-10.5%	22%	84	+11.6%	22%	340	+2.1%	88%
Effient (alliance revenue)	20	+401.5%	-	22	+151.6%	-	24	+90.2%	-	35	+134.1%	-	100	+150.1%	-
USD Mn															
Luitpold Pharmaceuticals, Inc. (US)	156	-2.8%	26%	121	-24.2%	21%	193	+36.4%	33%	96.0	-42.8%	16%	566	-10.0%	96%
Venofer	90	-1.5%	30%	71	-20.7%	24%	116	+60.8%	39%	36	-65.0%	12%	314	-12.2%	104%
EUR Mn															
Daiichi Sankyo Europe GmbH	144	+13.6%	21%	153	+2.7%	23%	165	+2.5%	25%	182.0	+21.5%	27%	644	+9.8%	96%
Olmesartan	101	+23.1%	21%	110	+5.1%	23%	121	+1.3%	25%	136	+33.5%	29%	468	+14.7%	98%
Olmetec/Olmetec Plus	74	+9.4%	21%	80	-4.4%	23%	88	-2.0%	25%	95	+13.4%	27%	336	+3.7%	97%
Sevikar	21	+43.7%	20%	24	+11.5%	23%	25	+21.1%	24%	32	+75.2%	30%	101	+35.9%	97%
Sevikar HCT	6	-	24%	6	-	25%	8	-10.6%	31%	10	+1366.1%	39%	31	+218.7%	119%
Efient (alliance revenue)	5	-	-	6	-	-	7	-	-	10	-	-	27	-	-
INR Bn															
Ranbaxy Laboratories Limited	22	-21.5%	26%	21	-1.5%	25%	21	+8.0%	25%	38.0	+82.4%	45%	101	+13.9%	119%

5. Sales of Global Products (FY2011)

	Q1			Q2			Q3			Q4			FY2011		
	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan	Results	YoY	to plan
JPY Bn															
Olmesartan	63.3	+5.2%	24%	60.4	-1.6%	22%	64.2	-2.3%	24%	61.7	+13.9%	23%	249.7	+3.4%	93%
Olmetec (JPN)	20.4	-1.3%	22%	20.4	-3.1%	22%	22.6	-1.4%	24%	17.4	-1.2%	19%	80.9	-1.8%	87%
Rezaltas (JPN)	2.9	+58.1%	17%	3.2	+3938.1%	19%	3.9	+190.8%	23%	3.5	+145.4%	21%	13.5	+188.4%	79%
Benicar/Benicar HCT (US)	20.1	-6.1%	30%	16.8	-18.7%	25%	16.2	-21.3%	24%	18.1	+6.6%	27%	71.3	-10.6%	106%
Azor (US)	3.6	-7.0%	26%	2.5	-26.5%	18%	3.2	-8.7%	23%	2.8	+7.5%	21%	12.0	-9.5%	89%
Tribenzor (US)	1.2	-	16%	1.1	+71.6%	15%	1.2	+139.2%	16%	1.1	+271.8%	15%	4.6	+217.4%	62%
Olmetec/Olmetec Plus (EU)	8.7	+9.8%	22%	8.8	-5.1%	22%	9.2	-8.4%	23%	9.9	+5.4%	25%	36.6	-0.1%	92%
Sevikar (EU)	2.4	+44.1%	20%	2.6	+10.5%	22%	2.6	+13.1%	22%	3.3	+63.9%	28%	11.0	+30.9%	92%
Sevikar HCT (EU)	0.7	-	25%	0.7	-	24%	0.9	-16.6%	29%	1.1	+1296.8%	36%	3.4	+206.9%	113%
Other subsidiaries, export, etc	3.3	+16.4%	20%	4.3	+10.4%	25%	4.4	+28.8%	26%	4.5	+18.3%	26%	16.5	+18.3%	97%
Levofloxacin	13.5	-20.2%	26%	12.8	-24.1%	24%	13.9	-23.3%	26%	12.2	-29.1%	23%	52.4	-24.2%	99%
Cravit (JPN)	8.4	+8.5%	22%	8.4	+11.5%	22%	10.8	+16.8%	29%	8.7	+11.4%	23%	36.3	+12.3%	96%
Export, royalty, etc	3.1	-56.2%	45%	2.3	-67.5%	33%	1.2	-82.6%	17%	1.6	-78.3%	22%	8.1	-71.0%	116%
Other subsidiaries	2.0	-4.7%	25%	2.1	-4.9%	26%	1.9	-12.9%	23%	2.0	-11.9%	25%	7.9	-8.6%	99%
Pravastatin	10.2	-13.9%	27%	10.0	-15.5%	26%	10.6	-8.6%	28%	8.4	-12.6%	22%	39.2	-12.7%	103%
Mevalotin (JPN)	8.8	-14.0%	27%	8.6	-14.4%	27%	8.8	-11.6%	28%	6.8	-12.0%	21%	33.1	-13.1%	103%
Other subsidiaries, export, etc	1.5	-12.9%	25%	1.3	-22.1%	22%	1.7	+10.7%	29%	1.6	-15.1%	26%	6.1	-10.4%	102%
Prasugrel	2.2	+176.5%	-	2.3	+134.2%	-	2.6	+72.6%	-	3.8	+94.3%	-	10.9	+108.2%	-
Effient alliance revenue (US)	1.6	+345.5%	-	1.7	+124.3%	-	1.9	+75.5%	-	2.8	+119.8%	-	7.9	+130.7%	-
Efient alliance revenue (EU)	0.6	+34.9%	-	0.6	+165.9%	-	0.7	+65.5%	-	1.0	+47.9%	-	2.9	+64.8%	-

n

1. Summary of Consolidated Income Statement (FY2010)

JPY Bn	Q1			Q2			Q3			Q4			FY2010			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	256.4	+12.9%	100%	242.5	-0.4%	100%	249.2	-2.3%	100%	219.3	-3.2%	100%	967.4	15.3	+1.6%
Cost of sales	25%	64.1	+2.5%	31%	74.4	-0.4%	30%	74.6	-1.1%	31%	68.6	+5.0%	29%	281.7	3.6	+1.3%
Gross Profit	75%	192.4	+16.9%	69%	168.0	-0.4%	70%	174.6	-2.8%	69%	150.7	-6.4%	71%	685.7	11.6	+1.7%
SG&A expenses	51%	131.3	-4.7%	57%	139.0	-3.9%	58%	144.1	+2.6%	68%	149.2	-4.1%	58%	563.5	-15.0	-2.6%
R&D expenses	17%	43.6	-3.4%	19%	45.7	-6.7%	21%	53.0	+11.4%	24%	52.0	-5.6%	20%	194.3	-2.5	-1.3%
Other expenses	34%	87.7	-5.4%	38%	93.3	-2.5%	37%	91.1	-2.0%	44%	97.2	-3.3%	38%	369.2	-12.5	-3.3%
Operating Income	24%	61.1	+128.1%	12%	29.0	+20.6%	12%	30.5	-22.2%	1%	1.5	-72.2%	13%	122.1	26.6	+27.9%
Non-operating income / expenses		9.0			-6.5			7.4			-0.4			9.6	2.0	
Non-operating income		11.8			-1.7			7.5			5.6			23.2	-5.0	
Non-operating expenses		2.8			4.8			0.0			6.0			13.6	-7.0	
Ordinary Income	27%	70.1	+877.7%	9%	22.6	-50.0%	15%	38.0	-1.1%	1%	1.2	-90.7%	14%	131.8	28.6	+27.8%
Extraordinary income / losses		-4.0			5.5			-1.2			-11.6			-11.3	-5.6	
Extraordinary income		0.8			6.8			0.9			4.3			12.8	6.9	
Extraordinary losses		4.8			1.3			2.2			15.9			24.2	12.5	
Income before income taxes and minority interests	26%	66.1	+665.1%	12%	28.0	-37.7%	15%	36.7	-1.6%	-5%	-10.4	-	12%	120.4	23.0	+23.7%
Income taxes / minority interests		33.0			9.0			9.2			-0.9			50.3	-5.2	
Income taxes		26.6			8.2			8.0			-0.9			41.8	-8.2	
Minority interests		6.5			0.8			1.2			0.0			8.5	3.0	
Net Income	13%	33.1	-	8%	19.1	-24.1%	11%	27.5	+33.8%	-4%	-9.5	-	7%	70.1	28.3	+67.5%
Effective tax rate		40%			29%			22%			-			35%		
Overseas sales ratio results		52%			51%			46%			53%			51%		

2. Currency Rate (FY2010)

	Q1		Q2 YTD		Q3 YTD		Q4 YTD		FY2010	
	Results		Results		Results		Results		Results	YoY
USD/JPY (average)	92.02		88.95		86.53		85.72		85.72	-7.14
EUR/JPY (average)	117.00		113.84		113.31		113.13		113.13	-18.03
INR/JPY (average)	1.98		2.01		1.96		1.93		1.93	-0.02

3. Segment Information (FY2010)

Daiichi Sankyo Group	Q1			to sales	Q2			to sales	Q3			to sales	Q4			FY2010			
	to sales	Results	YoY		to sales	Results	YoY		to sales	Results	YoY		to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	201.6	+2.1%		100%	198.8	-4.0%		100%	213.7	-2.4%		100%	181.3	-0.3%	100%	795.5	-10.0	-1.2%
Cost of sales	22%	44.9	-1.1%		27%	54.4	+0.1%		26%	55.0	-1.1%		26%	47.6	+0.5%	25%	201.8	-0.8	-0.4%
Gross Profit	78%	156.7	+3.1%		73%	144.4	-5.4%		74%	158.8	-2.9%		74%	133.8	-0.6%	75%	593.7	-9.1	-1.5%
SG&A expenses	56%	113.5	-7.0%		61%	121.2	-4.2%		60%	127.7	+2.7%		73%	131.5	-2.5%	62%	493.9	-13.7	-2.7%
R&D expenses	20%	40.3	-6.2%		22%	43.5	-6.9%		24%	50.6	+12.0%		27%	49.6	-4.0%	23%	184.0	-2.5	-1.3%
Other expenses	36%	73.2	-7.4%		39%	77.7	-2.6%		36%	77.1	-2.6%		45%	81.9	-1.5%	39%	309.9	-11.2	-3.5%
Operating Income	22%	43.3	+44.0%		12%	23.2	-11.6%		15%	31.1	-20.6%		1%	2.3	-1422.3%	13%	99.8	4.6	+4.8%
Non-operating income		1.8				1.9				2.6				0.9			7.2	0.2	
Non-operating expenses		1.7				2.0				-0.1				3.4			7.0	0.9	
Ordinary Income	22%	43.4	+34.8%		12%	23.1	-12.6%		16%	33.7	-12.9%		0%	-0.2	-	13%	100.0	3.8	+4.0%
Extraordinary income		0.8				3.8				1.4				4.3			10.2	5.7	
Extraordinary losses		4.2				1.0				0.7				15.0			20.9	9.3	
Income before income taxes and minority interests	20%	40.0	+18.8%		13%	25.9	-1.6%		16%	34.4	-8.6%		-6%	-10.9	-	11%	89.3	0.2	+0.2%
Income taxes		17.7				7.5				8.5				-3.1			30.6	-23.7	
Minority interests																			
Net Income	11%	22.3	+122.8%		9%	18.3	+39.4%		12%	26.0	+30.0%		-4%	-7.8	-	7%	58.8	23.9	+68.6%
Ranbaxy Group																			
Net sales	100%	54.9	+84.9%		100%	43.8	+20.1%		100%	35.5	-1.4%		100%	38.9	-12.6%	100%	173.1	26.4	+18.0%
Cost of sales	35%	19.2	+12.0%		46%	20.0	-1.8%		55%	19.5	-1.7%		54%	21.0	+16.6%	46%	79.8	4.4	+5.8%
Gross Profit	65%	35.7	+184.1%		54%	23.7	+48.0%		45%	16.0	-1.1%		46%	17.9	-32.5%	54%	93.3	22.1	+31.0%
SG&A expenses	30%	16.4	+13.9%		39%	17.1	+2.9%		43%	15.4	+5.3%		43%	16.7	-13.5%	38%	65.6	0.7	+1.0%
R&D expenses	6%	3.3	+56.2%		7%	3.0	+32.0%		8%	2.8	+19.0%		7%	2.8	-19.0%	7%	12.0	1.7	+16.7%
Other expenses	24%	13.1	+6.7%		32%	14.1	-1.8%		35%	12.5	+2.6%		36%	13.9	-12.3%	31%	53.5	-1.1	-2.0%
Operating Income	35%	19.3	-1171.9%		15%	6.6	-1214.7%		2%	0.6	-60.0%		3%	1.1	-83.9%	16%	27.7	21.4	+338.8%
Non-operating income		10.0				-3.0				4.9				4.2			16.2	-5.0	
Non-operating expenses		1.1				2.7				0.1				0.1			3.9	-10.5	
Ordinary Income	52%	28.3	-220.1%		2%	0.9	-95.4%		16%	5.5	+374.9%		14%	5.3	-65.1%	23%	40.0	27.0	+207.8%
Extraordinary income		0.0				5.2				0.0				-0.1			5.1	3.8	
Extraordinary losses		0.7				0.1				1.5				6.0			8.3	8.2	
Income before income taxes and minority interests	50%	27.6	-217.5%		14%	6.0	-70.2%		11%	4.0	+249.7%		-2%	-0.8	-	21%	36.8	22.6	+158.6%
Income taxes		9.2				1.5				0.1				2.4			13.2	3.4	
Minority interests		0.1				0.1				0.1				0.1			0.3	0.1	
Net Income	33%	18.4	-		10%	4.5	-68.3%		11%	3.8	-		-9%	-3.3	-	14%	23.3	19.1	+456.4%
Inter-segment Transactions																			
Net sales		-0.1				-0.1				-0.1				-0.9			-1.2		
Cost of sales		0.0				0.0				0.1				0.0			0.1		
Gross Profit		-0.1				-0.1				-0.2				-0.9			-1.3		
SG&A expenses		1.5				0.7				1.0				1.0			4.1		
R&D expenses		0.0				-0.8				-0.4				-0.4			-1.7		
Other expenses		1.5				1.5				1.4				1.4			5.8		
Operating Income		-1.5				-0.7				-1.2				-1.9			-5.4		
Non-operating income		0.0				-0.7				-0.1				0.5			-0.2		
Non-operating expenses						0.1				0.0				2.5			2.6		
Ordinary Income		-1.5				-1.5				-1.3				-3.9			-8.2		
Extraordinary income		0.0				-2.2				-0.5				0.1			-2.5		
Extraordinary losses						0.2				0.0				-5.2			-5.0		
Income before income taxes and minority interests		-1.5				-3.9				-1.7				1.4			-5.7		
Income taxes		-0.3				-0.8				-0.6				-0.2			-2.0		
Minority interests		6.4				0.7				1.1				-0.1			8.2		
Net Income		-7.6				-3.8				-2.2				1.6			-12.0		

4. Sales by Business Units (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Consolidated Net Sales	256.4	+12.9%	242.5	-0.4%	249.2	-2.3%	219.3	-3.2%	967.4	+1.6%
Japan Company (domestic sales)	105.3	+0.6%	103.0	-1.7%	116.8	-1.4%	91.0	+7.6%	416.0	+0.9%
Olmotec	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Calblock	3.7	+6.5%	3.5	+0.6%	3.8	-0.6%	2.9	+1.3%	14.0	+1.9%
Loxonin	13.0	+15.9%	13.9	+11.0%	14.7	+10.0%	12.6	+27.3%	54.2	+15.3%
Cravit	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Mevalotin	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Artist	6.1	+1.8%	5.8	-1.6%	6.3	-0.9%	5.4	+8.5%	23.7	+1.6%
Omnipaque	6.4	-10.1%	6.6	-12.4%	6.5	-8.5%	5.4	-0.2%	25.0	-8.3%
Urief	2.5	+11.2%	2.5	+9.2%	2.8	+9.2%	2.3	+16.5%	10.1	+11.3%
Inavir	-	-	-	-	2.8	-	3.9	-	6.6	-
Vaccines	1.7	+36.2%	4.6	+139.8%	8.5	-1.2%	2.9	+128.3%	17.8	+35.6%
Daiichi Sankyo Espha products	-	-	-	-	2.6	-	2.0	-	4.6	-
Daiichi Sankyo Healthcare (OTC)	9.3	-2.7%	11.7	-12.9%	13.2	+9.1%	10.6	+23.2%	44.8	+2.6%
Daiichi Sankyo, Inc. (US)	33.6	+1.7%	33.9	+1.2%	34.6	+0.6%	28.4	-11.6%	130.5	-1.9%
Olmesartan	25.2	+0.6%	24.7	-2.5%	24.6	-6.9%	19.9	-19.8%	94.5	-7.1%
Benicar/Benicar HCT	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor	-	-	0.7	-	0.5	-	0.3	-	1.5	-
Welchol	7.0	+1.8%	7.4	+13.4%	7.9	+7.6%	6.3	-8.3%	28.5	+3.6%
Effient (alliance revenue)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Luitpold Pharmaceuticals, Inc. (US)	14.7	+10.4%	13.7	+1.3%	11.5	-8.5%	14.0	+10.5%	53.9	+3.5%
Venofer	8.4	+5.2%	7.7	-5.0%	5.8	-27.1%	8.7	+8.4%	30.7	-4.6%
Daiichi Sankyo Europe GmbH	14.8	-14.6%	16.6	-10.0%	18.1	-5.0%	16.9	-17.2%	66.4	-11.7%
Olmesartan	9.6	+4.5%	11.7	+4.5%	13.4	+7.9%	11.5	-14.7%	46.2	-0.2%
Olmotec/Olmotec Plus	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT	-	-	-	-	1.0	-	0.1	-	1.1	-
Asia, South and Central America (ASCA)	5.9	+12.7%	7.1	+12.8%	6.8	+3.3%	7.6	-0.4%	27.4	+6.4%
Daiichi Sankyo Pharmaceutical (Beijing)	1.1	+17.8%	1.1	+3.6%	1.1	-6.3%	0.9	-2.2%	4.2	+2.9%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.4	+35.5%	1.7	+32.5%	1.6	+10.5%	1.8	+20.7%	6.6	+23.8%
Daiichi Sankyo Taiwan	0.8	-8.6%	0.8	+1.0%	0.8	+13.5%	1.0	+29.2%	3.4	+7.9%
Daiichi Sankyo Korea	1.0	+31.4%	0.9	+2.9%	1.0	+9.7%	1.1	+29.6%	4.0	+17.9%
Daiichi Sankyo (Thailand)	0.2	+35.8%	0.3	+22.8%	0.3	+53.4%	0.3	+26.9%	1.2	+33.8%
Daiichi Sankyo Brasil Farmacêutica	1.0	+36.5%	1.4	+39.5%	1.4	+6.4%	1.3	-19.9%	5.2	+9.5%
Daiichi Sankyo Venezuela	0.4	-46.7%	0.7	-18.7%	0.6	-25.1%	1.1	-32.7%	2.9	-30.5%
Ranbaxy Laboratories Limited	54.8	+84.7%	43.7	+19.9%	35.4	-1.6%	38.0	-14.5%	171.9	+17.3%
Others	18.0	+25.6%	12.8	-25.1%	12.7	-20.2%	12.8	-20.0%	56.3	-11.1%
Levofloxacin export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Efient alliance revenue (Europe)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

[Reference] Sales in Local Currency (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
Daiichi Sankyo, Inc. (US)	365	+7.6%	394	+10.2%	422	+10.3%	342	-3.3%	1,522	+6.3%
Olmesartan	274	+6.4%	287	+6.2%	300	+2.3%	241	-12.2%	1,102	+0.6%
Benicar/Benicar HCT	233	+2.7%	241	+1.6%	251	-0.5%	205	-15.2%	930	-2.9%
Azor	42	+33.1%	39	+16.9%	42	+4.6%	32	-1.0%	155	+12.7%
Tribenzor	-	-	7	-	6	-	4	-	17	-
Welchol	76	+7.6%	85	+23.1%	95	+17.8%	76	+0.3%	333	+12.2%
Effient (alliance revenue)	4	-	9	-	13	-	15	-	40	-
USD Mn										
Luitpold Pharmaceuticals, Inc. (US)	160	+16.7%	159	+10.6%	142	+1.2%	168	+20.1%	629	+12.1%
Venofer	92	+11.3%	90	+3.8%	72	-18.5%	104	+17.5%	358	+3.4%
EUR Mn										
Daiichi Sankyo Europe GmbH	126	-3.2%	149	+8.3%	161	+12.1%	150	-7.0%	587	+2.3%
Olmesartan	82	+18.4%	105	+25.4%	119	+27.3%	102	-3.9%	408	+15.7%
Olmetec/Olmetec Plus	68	+8.5%	83	+12.0%	90	+16.1%	83	-7.6%	324	+6.5%
Sevikar	14	+109.5%	21	+136.0%	20	+24.9%	18	+12.8%	74	+53.6%
Sevikar HCT	-	-	-	-	9	-	1	-	10	-
INR Bn										
Ranbaxy Laboratories Limited	28	+76.3%	21	+17.1%	19	+4.6%	21	-9.0%	89	+18.5%

5. Sales of Global Products (FY2010)

	Q1		Q2		Q3		Q4		FY2010	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Olmesartan	60.2	+7.6%	61.4	+3.4%	65.7	+1.6%	54.2	-7.0%	241.5	+1.4%
Olmetec (JPN)	20.7	+8.7%	21.1	+6.5%	23.0	+3.5%	17.6	+8.5%	82.3	+6.6%
Rezaltas (JPN)	1.8	-	0.1	-	1.3	-	1.4	-	4.7	-
Benicar/Benicar HCT (US)	21.4	-2.9%	20.7	-6.8%	20.6	-9.4%	17.0	-22.5%	79.7	-10.4%
Azor (US)	3.8	+25.8%	3.4	+6.8%	3.5	-5.3%	2.6	-9.7%	13.3	+4.1%
Tribenzor (US)	-	-	-	-	0.5	-	0.3	-	1.5	-
Olmetec/Olmetec Plus (EU)	7.9	-4.2%	9.3	-6.7%	10.1	-1.6%	9.4	-17.9%	36.7	-8.1%
Sevikar (EU)	1.7	+84.9%	2.4	+97.4%	2.3	+5.7%	2.0	-0.4%	8.4	+32.5%
Sevikar HCT (EU)	-	-	-	-	1.0	-	0.1	-	1.1	-
Other subsidiaries, export, etc	2.8	+7.7%	3.9	+25.4%	3.5	-6.2%	3.8	+0.8%	13.9	+6.0%
Levofloxacin	17.0	-14.3%	16.9	-28.0%	18.1	-18.3%	17.2	-21.1%	69.1	-20.7%
Cravit (JPN)	7.8	-18.3%	7.5	-36.7%	9.3	-14.5%	7.8	-31.7%	32.4	-25.8%
Export, royalty, etc	7.1	-16.2%	7.2	-25.3%	6.6	-27.5%	7.2	-16.8%	28.1	-21.7%
Other subsidiaries	2.1	+15.8%	2.2	+10.6%	2.1	+2.0%	2.2	+25.6%	8.7	+12.9%
Pravastatin	11.9	-19.1%	11.8	-21.5%	11.6	-21.8%	9.6	-8.3%	44.9	-18.4%
Mevalotin (JPN)	10.2	-17.9%	10.1	-18.9%	10.0	-22.0%	7.8	-8.8%	38.1	-17.6%
Other subsidiaries, export, etc	1.7	-25.8%	1.7	-34.1%	1.6	-20.9%	1.8	-6.1%	6.8	-22.8%
Prasugrel (alliance revenue)	0.8	-	1.0	-	1.5	-	2.0	-	5.2	+889.6%
Effient alliance revenue (US)	0.4	-	0.8	-	1.1	-	1.3	-	3.4	-
Efient alliance revenue (EU)	0.4	-	0.2	-	0.4	+278.5%	0.7	+97.7%	1.8	+285.9%

1. Summary of Consolidated Income Statement (FY2009)

JPY Bn	Q1			Q2			Q3			Q4			FY2009			
	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	227.1	+11.5%	100%	243.4	+20.2%	100%	255.1	+15.3%	100%	226.4	+5.6%	100%	952.1	110.0	+13.1%
Cost of sales	28%	62.5	+28.5%	31%	74.7	+52.5%	30%	75.4	+41.9%	29%	65.4	+2.8%	29%	278.0	63.6	+29.7%
Gross Profit	72%	164.6	+6.1%	69%	168.7	+9.8%	70%	179.7	+6.8%	71%	161.1	+6.7%	71%	674.1	46.3	+7.4%
SG&A expenses	61%	137.8	+19.8%	59%	144.6	+9.6%	55%	140.5	+6.6%	69%	155.6	-2.8%	61%	578.6	39.7	+7.4%
R&D expenses	20%	45.1	+22.2%	20%	49.0	+7.9%	19%	47.6	+1.6%	24%	55.1	-0.5%	21%	196.8	12.3	+6.6%
Other expenses	41%	92.7	+18.6%	39%	95.6	+10.5%	36%	92.9	+9.4%	44%	100.5	-4.0%	40%	381.8	27.4	+7.7%
Operating Income	12%	26.8	-33.1%	10%	24.1	+11.5%	15%	39.2	+7.6%	2%	5.4	-	10%	95.5	6.6	+7.5%
Non-operating income / expenses		-19.6			21.0			-0.8			7.0			7.6	41.3	
Non-operating income		3.9			10.9			4.3			9.1			28.2	15.9	
Non-operating expenses		23.5			-10.1			5.1			2.1			20.6	-25.4	
Ordinary Income	3%	7.2	-82.5%	19%	45.1	+140.0%	15%	38.4	+14.4%	6%	12.5	-	11%	103.1	47.9	+86.9%
Extraordinary income / losses		1.5			-0.1			-1.1			-6.1			-5.7	357.7	
Extraordinary income		2.1			0.2			1.5			2.1			5.9	2.1	
Extraordinary losses		0.7			0.3			2.5			8.1			11.6	-355.6	
Income before income taxes and minority interests	4%	8.6	-78.2%	18%	45.0	+164.3%	15%	37.3	-	3%	6.4	-	10%	97.4	405.6	-
Income taxes / minority interests		15.1			19.9			16.8			3.8			55.5	148.3	
Income taxes		24.0			12.8			16.0			-2.7			50.0	129.2	
Minority interests		-8.9			7.1			0.7			6.5			5.5	19.1	
Net Income	-3%	-6.4	-	10%	25.1	+182.7%	8%	20.6	-	1%	2.6	-96.8%	4%	41.9	257.4	-
Effective tax rate		278%			28%			43%			-			51%		
Overseas sales ratio results		48%			50%			47%			57%			51%		

2. Currency Rate (FY2009)

	Q1	Q2 YTD	Q3 YTD	Q4 YTD	FY2009	
	Results	Results	Results	Results	Results	YoY
USD/JPY (average)	97.33	95.50	93.57	92.86	92.86	-7.68
EUR/JPY (average)	132.58	133.16	133.00	131.16	131.16	-12.33
INR/JPY (average)	1.89	1.95	1.95	1.95	1.95	-0.05

3. Segment Information (FY2009)

Daiichi Sankyo Group	Q1			to sales	Q2			to sales	Q3			to sales	Q4			FY2009			
	to sales	Results	YoY		to sales	Results	YoY		to sales	Results	YoY		to sales	Results	YoY	to sales	Results	YoY	YoY
Net sales	100%	197.4	-3.1%		100%	207.0	+2.2%		100%	219.1	-1.0%		100%	181.9	+3.4%	100%	805.5	1.9	+0.2%
Cost of sales	23%	45.4	-6.7%		26%	54.3	+10.9%		25%	55.6	+4.6%		26%	47.3	+14.6%	25%	202.6	10.5	+5.5%
Gross Profit	77%	152.0	-2.0%		74%	152.7	-0.6%		75%	163.5	-2.8%		74%	134.6	+0.0%	75%	602.8	-8.6	-1.4%
SG&A expenses	62%	122.0	+6.0%		61%	126.5	-4.2%		57%	124.3	-1.5%		74%	134.8	+3.3%	63%	507.6	3.8	+0.8%
R&D expenses	22%	43.0	+16.5%		23%	46.7	+2.8%		21%	45.2	-3.5%		28%	51.6	+12.4%	23%	186.5	11.4	+6.5%
Other expenses	40%	79.0	+1.1%		39%	79.8	-7.8%		36%	79.1	-0.3%		46%	83.2	-1.7%	40%	321.1	-7.7	-2.3%
Operating Income	15%	30.0	-24.9%		13%	26.2	+21.3%		18%	39.1	-6.7%		0%	-0.2	-	12%	95.2	-12.4	-11.5%
Non-operating income		2.9				2.0				1.8				0.4			7.1	-3.8	
Non-operating expenses		0.8				1.8				2.2				1.4			6.1	-13.9	
Ordinary Income	16%	32.2	-21.3%		13%	26.4	+40.5%		18%	38.7	-0.8%		-1%	-1.1	-	12%	96.1	-2.2	-2.3%
Extraordinary income		2.1				0.2				1.5				0.8			4.6	0.9	
Extraordinary losses		0.7				0.3				2.5				8.1			11.6	-4.0	
Income before income taxes and minority interests	17%	33.6	-15.0%		13%	26.3	+54.4%		17%	37.7	+0.5%		-5%	-8.5	-	11%	89.1	2.7	+3.2%
Income taxes		23.6				13.1				17.7				-0.2			54.3	17.8	
Minority interests																			
Net Income	5%	10.0	-60.1%		6%	13.2	+48.0%		9%	20.0	-27.9%		-5%	-8.3	-	4%	34.8	-15.1	-30.2%
Ranbaxy Group																			
Net sales	100%	29.7			100%	36.4			100%	36.0			100%	44.5	+15.1%	100%	146.7	108.0	
Cost of sales	58%	17.1			56%	20.4			55%	19.8			41%	18.1	-12.0%	51%	75.4	54.9	
Gross Profit	42%	12.6			44%	16.0			45%	16.2			59%	26.4	+45.8%	49%	71.2	53.1	
SG&A expenses	48%	14.4			46%	16.6			41%	14.6			43%	19.3	+10.0%	44%	64.9	47.4	
R&D expenses	7%	2.1			6%	2.3			7%	2.4			8%	3.5	+35.7%	7%	10.3	7.7	
Other expenses	41%	12.3			39%	14.3			34%	12.2			36%	15.8	+5.6%	37%	54.6	39.6	
Operating Income	-6%	-1.8			-2%	-0.6			4%	1.6			16%	7.1	+1119.4%	4%	6.3	5.7	
Non-operating income		1.0				9.0				2.5				8.7			21.1	19.7	
Non-operating expenses		22.7				-11.9				2.9				0.7			14.5	-11.5	
Ordinary Income	-79%	-23.5			56%	20.2			3%	1.2			34%	15.1	-	9%	13.0	36.9	
Extraordinary income		0.0				0.0				0.0				1.3			1.3	1.2	
Extraordinary losses										0.0				0.1			0.1	-0.2	
Income before income taxes and minority interests	-79%	-23.5			56%	20.2			3%	1.1			37%	16.4	-	10%	14.2	38.3	
Income taxes		-6.6				6.0				1.3				9.2			9.8	17.7	
Minority interests		0.0				0.0				0.1				0.1			0.2	0.1	
Net Income	-57%	-16.9			39%	14.2			-1%	-0.2			16%	7.1	-	3%	4.2	20.4	
Inter-segment Transactions																			
Net sales																			
Cost of sales																			
Gross Profit																			
SG&A expenses		1.5				1.5				1.5				1.5			6.0		
R&D expenses																			
Other expenses		1.5				1.5				1.5				1.5			6.0		
Operating Income		-1.5				-1.5				-1.5				-1.5			-6.0		
Non-operating income																			
Non-operating expenses																			
Ordinary Income		-1.5				-1.5				-1.5				-1.5			-6.0		
Extraordinary income																			
Extraordinary losses																			
Income before income taxes and minority interests		-1.5				-1.5				-1.5				-1.5			-6.0		
Income taxes		7.0				-6.4				-3.0				-11.8			-14.1		
Minority interests		-8.9				7.1				0.7				6.5			5.3		
Net Income		0.5				-2.3				0.8				3.8			2.8		

4. Sales by Business Units (FY2009)

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Consolidated Net Sales	227.1	11.5%	243.4	20.2%	255.1	15.3%	226.4	5.6%	952.1	13.1%
Japan Company (domestic sales)	104.6	3.7%	104.8	5.3%	118.4	-1.4%	84.5	-1.9%	412.3	1.4%
Olmotec	19.0	22.1%	19.8	26.1%	22.2	18.8%	16.2	12.5%	77.2	20.0%
Calblock	3.5	14.5%	3.5	18.9%	3.8	12.5%	2.9	4.7%	13.7	12.8%
Loxonin	11.2	33.0%	12.5	19.7%	13.3	16.0%	9.9	19.4%	47.0	21.4%
Cravit	9.5	-6.8%	11.9	26.7%	10.8	-21.0%	11.4	17.5%	43.6	1.5%
Mevalotin	12.4	-8.3%	12.4	-5.0%	12.8	-9.1%	8.5	-14.7%	46.2	-8.9%
Artist	6.0	6.3%	5.9	11.3%	6.4	6.0%	5.0	1.9%	23.3	6.5%
Omnipaque	7.1	-2.0%	7.5	3.4%	7.1	-10.8%	5.5	-4.8%	27.3	-3.7%
Urief	2.2	26.6%	2.2	26.1%	2.6	19.3%	2.0	-9.9%	9.0	14.3%
Vaccines	1.3	235.0%	1.9	40.4%	8.6	22.9%	1.3	151.5%	13.1	41.0%
Daiichi Sankyo Healthcare (OTC)	9.5	-6.9%	13.5	-2.1%	12.1	-8.2%	8.6	-14.1%	43.7	-7.4%
Daiichi Sankyo, Inc. (US)	33.0	-11.2%	33.5	5.6%	34.4	5.8%	32.1	15.2%	133.0	2.9%
Olmесartan	25.1	1.5%	25.4	3.5%	26.4	5.9%	24.9	13.6%	101.7	5.9%
Benicar/Benicar HCT	22.1	-5.6%	22.2	0.5%	22.7	2.0%	21.9	11.7%	88.9	1.8%
Azor	3.0	121.5%	3.2	30.9%	3.6	38.6%	2.9	29.7%	12.8	47.2%
Welchol	6.9	7.0%	6.5	6.6%	7.3	10.2%	6.8	28.2%	27.5	12.4%
Effient (alliance revenue)	-	-	1.0	-	0.2	-	-1.1	-	0.1	-
Luitpold Pharmaceuticals, Inc. (US)	13.4	-1.1%	13.5	-0.4%	12.6	-6.4%	12.7	18.9%	52.1	1.9%
Venofer	8.0	-3.9%	8.1	-4.6%	8.0	-4.1%	8.0	17.0%	32.2	0.3%
Daiichi Sankyo Europe GmbH	17.3	14.1%	18.4	-0.4%	19.1	6.1%	20.4	9.7%	75.2	7.1%
Olmесartan	9.2	10.7%	11.2	7.9%	12.4	17.9%	13.5	28.3%	46.3	16.5%
Olmotec/Olmotec Plus	8.3	-0.2%	10.0	-3.7%	10.2	12.1%	11.4	17.7%	39.9	6.5%
Sevikar	0.9	-	1.2	-	2.2	56.5%	2.0	156.5%	6.3	189.3%
Asia, South and Central America (ASCA)	5.3	0.5%	6.3	7.1%	6.6	11.7%	7.7	27.5%	25.8	12.1%
Daiichi Sankyo Pharmaceutical (Beijing)	1.0	-4.3%	1.1	7.6%	1.1	3.1%	0.9	1.4%	4.1	2.0%
Daiichi Sankyo Pharmaceutical (Shanghai)	1.1	48.0%	1.3	40.2%	1.4	35.2%	1.5	34.0%	5.3	38.4%
Daiichi Sankyo Taiwan	0.9	-8.6%	0.8	-14.9%	0.7	-14.4%	0.7	-4.5%	3.1	-10.7%
Daiichi Sankyo Korea	0.8	-15.6%	0.9	-2.1%	0.9	56.8%	0.9	38.9%	3.4	13.7%
Daiichi Sankyo (Thailand)	0.2	-0.9%	0.2	-0.4%	0.2	4.2%	0.3	27.4%	0.9	7.7%
Daiichi Sankyo Brasil Farmacêutica	0.8	-25.5%	1.0	-12.7%	1.3	-7.2%	1.6	18.4%	4.7	-5.2%
Daiichi Sankyo Venezuela	0.7	35.3%	0.9	45.0%	0.8	20.7%	1.7	76.3%	4.1	47.9%
Ranbaxy Laboratories Limited	29.7	-	36.4	-	36.0	-	44.4	14.9%	146.6	-
Others	14.4	-33.2%	17.1	-13.6%	15.9	-12.3%	16.0	-3.0%	63.4	-16.5%
Levofloxacin export, royalty, etc	8.5	-37.8%	9.6	-21.6%	9.2	-10.3%	8.6	-22.1%	35.9	-24.0%
Efient alliance revenue (Europe)	0.0	-	0.0	-	0.1	-	0.4	-	0.5	-

[Reference] Sales in Local Currency (FY2009)

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
USD Mn										
Daichi Sankyo, Inc. (US)	339	-4.6%	357	21.7%	382	13.4%	354	18.0%	1,433	11.4%
Olmesartan	258	9.0%	271	18.9%	293	13.9%	274	16.9%	1,095	14.6%
Benicar/Benicar HCT	227	1.4%	237	15.6%	253	9.7%	242	14.8%	958	10.2%
Azor	31	138.0%	34	49.3%	40	50.9%	32	35.4%	138	59.4%
Welchol	71	14.9%	69	22.8%	81	18.7%	75	31.4%	296	21.7%
Effient (alliance revenue)	-	-	10	-	2	-	-11	-	1	-
USD Mn										
Luitpold Pharmaceuticals, Inc. (US)	137	6.2%	144	14.5%	140	1.1%	140	21.4%	561	10.3%
Venofer	82	3.2%	87	9.6%	89	3.3%	89	19.8%	346	8.6%
EUR Mn										
Daichi Sankyo Europe GmbH	131	40.6%	138	20.8%	144	5.9%	161	9.8%	574	17.1%
Olmesartan	69	36.4%	83	30.9%	93	18.4%	106	28.1%	353	27.5%
Olmetec/Olmetec Plus	63	23.0%	74	16.7%	77	10.6%	90	17.2%	304	16.5%
Sevikar	7	-	9	-	16	77.6%	16	166.6%	48	216.5%
INR Bn										
Ranbaxy Laboratories Limited	16	-	18	-	18	-	23	17.9%	75	-

5. Sales of Global Products (FY2009)

	Q1		Q2		Q3		Q4		FY2009	
	Results	YoY	Results	YoY	Results	YoY	Results	YoY	Results	YoY
JPY Bn										
Olmesartan	56.0	10.5%	59.4	10.2%	64.7	12.3%	58.3	19.0%	238.3	12.9%
Olmetec (JPN)	19.0	22.1%	19.8	26.1%	22.2	18.8%	16.2	12.5%	77.2	20.0%
Benicar/Benicar HCT (US)	22.1	-5.6%	22.2	0.5%	22.7	2.0%	21.9	11.7%	88.9	1.8%
Azor (US)	3.0	121.5%	3.2	30.9%	3.6	38.6%	2.9	29.7%	12.8	47.2%
Olmetec/Olmetec Plus (EU)	8.3	-0.2%	10.0	-3.7%	10.2	12.1%	11.4	17.7%	39.9	6.5%
Sevikar (EU)	0.9	-	1.2	-	2.2	56.5%	2.0	156.5%	6.3	189.3%
Other subsidiaries, export, etc	2.6	29.9%	3.1	-7.8%	3.7	6.2%	3.7	71.4%	13.1	19.2%
Levofloxacin	19.8	-23.2%	23.5	-0.3%	22.1	-14.2%	21.8	-3.5%	87.2	-10.7%
Cravit (JPN)	9.5	-6.8%	11.9	26.7%	10.8	-21.0%	11.4	17.5%	43.6	1.5%
Export, royalty, etc	8.5	-37.8%	9.6	-21.6%	9.2	-10.3%	8.6	-22.1%	35.9	-24.0%
Other subsidiaries	1.8	-6.4%	2.0	2.9%	2.1	14.7%	1.8	-2.2%	7.7	2.2%
Pravastatin	14.7	-8.5%	15.0	-5.2%	14.8	-10.8%	10.5	-14.9%	55.0	-9.6%
Mevalotin (JPN)	12.4	-8.3%	12.4	-5.0%	12.8	-9.1%	8.5	-14.7%	46.2	-8.9%
Other subsidiaries, export, etc	2.3	-10.0%	2.6	-6.5%	2.0	-20.2%	2.0	-15.7%	8.8	-12.8%
Prasugrel (alliance revenue)	0.0	-	1.0	-	0.3	-	-0.7	-	0.5	-
Effient alliance revenue (US)	-	-	1.0	-	0.2	-	-1.1	-	0.1	-
Effient alliance revenue (EU)	0.0	-	0.0	-	0.1	-	0.4	-	0.5	-